Please enable JS

Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia

12/ 26

ARTICLE DETAILS

AUTHOR: 50SN Staff

DATE: Dec 26, 2017

TAGS:

SHARE ON: Twitter - Facebook - LinkedIn

Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia

A study found that Repatha® (evolocumab) significantly reduced LDL cholesterol in patients with and without elevated triglycerides compared to placebo and Zetia® (ezetimibe). Learn more about the differences among LDL, HDL and triglycerides from the American Heart Association.

Read more.


 

Font Resize